Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
INSP gained roughly 30% over the 21 trading days ending September 14. Inspire V is now used by more than three-quarters of implanting centers, EPS guidance was raised, and favorable physician adoption and 2026 reimbursement trends support continued momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Earnings deterioration ⢠Inventory buildup INSP has exceptional liquidity and cash generation, but sharply weakened profitability, rising inventory, and near-breakeven earnings warrant caution despite more reasonable valuation.
Price Behavior
Key Price Behavior Insights: ⢠Strong breakout ⢠New period high ⢠Extended momentum Support Level: $72.70â$74.60 Resistance Level: $76.78 (no confirmed overhead resistance) INSP surged 25% over the last month to a new $76.78 high, but its overbought momentum raises near-term pullback risk toward $72.70â$74.60 support.
Sentiment & News
Key News Insights: ⢠Inspire V adoption ⢠Reimbursement uncertainty ⢠Mixed institutional flows Inspire Medical's strong growth outlookâdriven by Inspire V adoption, clinical evidence, and market expansionâis tempered by reimbursement risks, recent share weakness, and mixed institutional activity.
AI Summary
INSP is a reimbursement-driven recovery thesisânot a proven growth compounderâwhere 2027 upside depends on coding clarity, improved provider economics, and successful Inspire V adoption restoring procedure volumes; despite strong cash reserves and 85% gross margins, investors should wait for volume and revenue confirmation as the recent rally has outpaced fundamentals.
Description
Inspire Medical Systems develops and markets minimally invasive treatments for obstructive sleep apnea in the United States and abroad. Its core product is an implanted hypoglossal nerve neurostimulation system used to treat moderate to severe OSA, and the company is progressing a closed-loop device that monitors respiration and delivers targeted stimulation to keep the airway open. The company was incorporated in 2007 and is based in Golden Valley, Minnesota.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 14 | Sep 21 | INSP | Inspire Medical Systems, Inc. | INSP gained roughly 30% over the 21 trading days ending September 14. Inspire V is now used by more than three-quarters of implanting centers, EPS guidance was raised, and favorable physician adoption and 2026 reimbursement trends support continued momentum. | Closed | +1.9% |
| Dec 2 | Dec 9 | INSP | Inspire Medical Systems, Inc. | Compelling short-term momentum with a 75% price surge over 21 days, driven by Q3 earnings beat, raised EPS guidance, growing Inspire V system adoption, positive reimbursement changes for 2026, but tempered by pending securities class-action risks and margin compression. | Closed | +5.0% |